Immunogenicity and safety of a third dose of anti-SARS-CoV-2 BNT16b2 vaccine in liver transplant recipients.

Pierluigi ToniuttoAnnarosa CussighSara CmetDavide BitettoEzio FornasiereElisa FumoloMartina FabrisFederica D'AurizioCarlo FabrisLucrezia GrilloneAssunta SartorFrancesco CurcioEdmondo Falleti

Published in: Liver international : official journal of the International Association for the Study of the Liver (2022)

The third dose of the BNT16b2 vaccine increased the number of LTs who developed a positive anti-SARS-CoV-2 s-RBD antibody response. A proportion of patients remained unresponsive, mainly for modifiable factors, such the use of MMF or multiple immunosuppressants.

Keyphrases

sars cov
end stage renal disease
respiratory syndrome coronavirus
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
coronavirus disease